Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104882 | 0.88 | METTL3 (0.44) | METTL3EGFRLMNAHTR1DHTR1B | |
| SCHEMBL4207612 | 0.86 | METTL3 (0.50) | METTL3EGFRLMNAHTR1DHTR1B | |
| SCHEMBL1104891 | 0.85 | METTL3 (0.56) | METTL3MRGPRX4CSF1RPLA2G4A | |
| SCHEMBL1104898 | 0.85 | METTL3 (0.49) | METTL3EGFRLMNAHTR1DHTR1B | |
| SCHEMBL4209881 | 0.84 | METTL3 (0.48) | METTL3LMNAMRGPRX4CSF1RPDE3B | |
| Hydrochloric Acid SCHEMBL4211289 | 0.84 | METTL3 (0.55) | METTL3MRGPRX4CSF1RPLA2G4A | |
| SCHEMBL1104896 | 0.81 | METTL3 (0.47) | METTL3EGFRLMNAMRGPRX4CSF1R | |
| SCHEMBL13927561 | 0.80 | METTL3 (0.48) | METTL3EGFRLMNAHTR1DHTR1B | |
| SCHEMBL4210123 | 0.79 | METTL3 (0.55) | METTL3EGFRLMNAMRGPRX4CSF1R | |
| SCHEMBL13927523 | 0.79 | METTL3 (0.48) | METTL3EGFRLMNAHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759525-B2 | Process and intermediates for preparing integrase inhibitors | Gilhead Sciences, Inc. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8440831-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8153801-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885LMNA 875/4885 |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885LMNA 875/4885 |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885LMNA 875/4885 |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885LMNA 875/4885 |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885EGFR 4014/4885LMNA 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.